Literature DB >> 12699772

Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis.

E R Anderson1, J Boyle, W E Zink, Y Persidsky, H E Gendelman, H Xiong.   

Abstract

Alterations in hippocampal physiology affect cognition in human immunodeficiency virus type 1 (HIV-1)-associated dementia (HAD). The mechanism for how this occurs is not well understood. To address this, we investigated how changes in synaptic transmission and plasticity are affected by viral infection and macrophage activation using a severe combined immunodeficiency mouse model of human HIV-1 encephalitis (HIVE). HIVE was induced in mice by stereotactic injection of HIV-1-infected human monocyte-derived macrophages (MDM) into the striatum. Animals were sacrificed after 3, 7 and 15 days. Hippocampal slices were prepared from HIV-1, MDM- and sham-injected animals. Electrically evoked field excitatory postsynaptic potentials were recorded in the CA1 region of the hippocampus. Neuronal physiology was assessed by input-output and by long-term potentiation (LTP) assays. We observed that a higher stimulation intensity (mA) was required to induce a 1-mV response in the HIVE mice (0.32+/-0.06) compared with shams (0.17+/-0.01) at day 7. The stimulation intensities at day 15 were 0.44+/-0.07 and 0.23+/-0.05 in the HIVE and shams, respectively. An impairment of synaptic function was detected through measuring synaptic responses induced by stimuli with different intensities. Paired-pulse facilitation (PPF) showed deficits in HIVE mice at days 3, 7, and 15. At day 3, PPF ratios were 1.13+/-0.02 and 1.24+/-0.04 in HIVE and sham. The induction and maintenance of LTP was also impaired in HIVE mice. The average magnitude of LTP was 131.23+/-15.26% of basal in HIVE as compared with sham animals of 232.63+/-24.18%. MDM-injected mice showed an intermediate response. Taken together, the results show a range of neuronal synaptic transmission and plasticity changes in HIVE mice that may reflect the mechanisms of cognitive dysfunction in human HAD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699772     DOI: 10.1016/s0306-4522(02)00925-9

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  23 in total

1.  FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders.

Authors:  Tomomi Kiyota; Kaitlin L Ingraham; Michael T Jacobsen; Huangui Xiong; Tsuneya Ikezu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-31       Impact factor: 11.205

Review 2.  Rodent models for HIV-associated neurocognitive disorders.

Authors:  Santhi Gorantla; Larisa Poluektova; Howard E Gendelman
Journal:  Trends Neurosci       Date:  2012-02-01       Impact factor: 13.837

Review 3.  Debate: "is increasing neuroinflammation beneficial for neural repair?".

Authors:  Keith A Crutcher; Howard E Gendelman; Jonathan Kipnis; J Regino Perez-Polo; V H Perry; Phillip G Popovich; Lynne C Weaver
Journal:  J Neuroimmune Pharmacol       Date:  2006-05-23       Impact factor: 4.147

4.  HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: implication for HIV-associated neurocognitive disorder (HAND).

Authors:  Zainulabedin M Saiyed; Nimisha Gandhi; Marisela Agudelo; Jessica Napuri; Thangavel Samikkannu; Pichili V B Reddy; Pradnya Khatavkar; Adriana Yndart; Shailendra K Saxena; Madhavan P N Nair
Journal:  Neurochem Int       Date:  2011-02-17       Impact factor: 3.921

5.  Glutaminase C overexpression in the brain induces learning deficits, synaptic dysfunctions, and neuroinflammation in mice.

Authors:  Yi Wang; Yuju Li; Runze Zhao; Beiqing Wu; Blaise Lanoha; Zenghan Tong; Justin Peer; Jianhui Liu; Huangui Xiong; Yunlong Huang; Jialin Zheng
Journal:  Brain Behav Immun       Date:  2017-06-15       Impact factor: 7.217

6.  Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis.

Authors:  Timothy J Spitzenberger; David Heilman; Casey Diekmann; Elena V Batrakova; Alexander V Kabanov; Howard E Gendelman; William F Elmquist; Yuri Persidsky
Journal:  J Cereb Blood Flow Metab       Date:  2006-10-25       Impact factor: 6.200

Review 7.  Glutamate metabolism and HIV-associated neurocognitive disorders.

Authors:  Fabián J Vázquez-Santiago; Richard J Noel; James T Porter; Vanessa Rivera-Amill
Journal:  J Neurovirol       Date:  2014-05-28       Impact factor: 2.643

Review 8.  Voltage-gated potassium channels in human immunodeficiency virus type-1 (HIV-1)-associated neurocognitive disorders.

Authors:  James Keblesh; Dehui Hu; Huangui Xiong
Journal:  J Neuroimmune Pharmacol       Date:  2008-05-06       Impact factor: 4.147

Review 9.  Neuronal injury in simian immunodeficiency virus and other animal models of neuroAIDS.

Authors:  Leslie Crews; Margaret R Lentz; R Gilberto Gonzalez; Howard S Fox; Eliezer Masliah
Journal:  J Neurovirol       Date:  2008-08       Impact factor: 2.643

10.  The severe combined immunodeficient (SCID) mouse model of human immunodeficiency virus encephalitis: deficits in cognitive function.

Authors:  William C Griffin; Lawrence D Middaugh; Jennifer E Cook; William R Tyor
Journal:  J Neurovirol       Date:  2004-04       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.